Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 27 | 2021 | 1026 | 3.370 |
Why?
|
| Bacteremia | 16 | 2022 | 155 | 2.440 |
Why?
|
| Communicable Diseases | 6 | 2022 | 50 | 2.140 |
Why?
|
| Gram-Negative Bacterial Infections | 8 | 2019 | 62 | 1.870 |
Why?
|
| Sepsis | 5 | 2022 | 233 | 1.460 |
Why?
|
| Anti-Infective Agents | 3 | 2018 | 166 | 1.110 |
Why?
|
| Antimicrobial Stewardship | 8 | 2022 | 33 | 1.100 |
Why?
|
| Social Media | 1 | 2022 | 59 | 0.750 |
Why?
|
| Cephalosporins | 2 | 2020 | 59 | 0.680 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2020 | 98 | 0.620 |
Why?
|
| Carbapenems | 1 | 2017 | 7 | 0.610 |
Why?
|
| Penicillins | 1 | 2017 | 32 | 0.600 |
Why?
|
| Drug Hypersensitivity | 1 | 2017 | 35 | 0.600 |
Why?
|
| Clostridium Infections | 4 | 2021 | 52 | 0.550 |
Why?
|
| beta-Lactams | 5 | 2019 | 29 | 0.520 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 649 | 0.520 |
Why?
|
| Enterobacteriaceae | 5 | 2019 | 29 | 0.510 |
Why?
|
| Polymyxins | 1 | 2014 | 3 | 0.490 |
Why?
|
| Students, Pharmacy | 2 | 2018 | 79 | 0.490 |
Why?
|
| Enterobacteriaceae Infections | 4 | 2019 | 25 | 0.480 |
Why?
|
| Inappropriate Prescribing | 1 | 2014 | 27 | 0.480 |
Why?
|
| Drug Utilization | 1 | 2014 | 119 | 0.470 |
Why?
|
| Vancomycin | 1 | 2014 | 60 | 0.460 |
Why?
|
| Pseudomonas Infections | 3 | 2020 | 83 | 0.450 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2020 | 133 | 0.450 |
Why?
|
| Fluoroquinolones | 4 | 2019 | 49 | 0.440 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 148 | 0.430 |
Why?
|
| Humans | 39 | 2022 | 68618 | 0.390 |
Why?
|
| Kidney Diseases | 1 | 2014 | 307 | 0.390 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 442 | 0.380 |
Why?
|
| Retrospective Studies | 15 | 2022 | 7277 | 0.350 |
Why?
|
| Cross Infection | 2 | 2021 | 195 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 767 | 0.320 |
Why?
|
| South Carolina | 10 | 2021 | 2752 | 0.310 |
Why?
|
| Pandemics | 2 | 2022 | 352 | 0.310 |
Why?
|
| Escherichia coli Infections | 2 | 2019 | 47 | 0.310 |
Why?
|
| Aged | 18 | 2022 | 14862 | 0.310 |
Why?
|
| Urinary Tract Infections | 2 | 2019 | 71 | 0.300 |
Why?
|
| Obesity | 1 | 2015 | 1076 | 0.300 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 156 | 0.290 |
Why?
|
| Female | 22 | 2020 | 38074 | 0.280 |
Why?
|
| Male | 21 | 2020 | 37321 | 0.280 |
Why?
|
| Middle Aged | 17 | 2020 | 21147 | 0.270 |
Why?
|
| Pharmacists | 3 | 2022 | 125 | 0.270 |
Why?
|
| Curriculum | 5 | 2022 | 575 | 0.260 |
Why?
|
| Area Under Curve | 4 | 2022 | 238 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 504 | 0.240 |
Why?
|
| Adult | 13 | 2022 | 21403 | 0.230 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 92 | 0.230 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 46 | 0.200 |
Why?
|
| Risk Factors | 8 | 2022 | 5731 | 0.200 |
Why?
|
| Drug Utilization Review | 1 | 2021 | 19 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4848 | 0.190 |
Why?
|
| Young Adult | 6 | 2020 | 5717 | 0.190 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2020 | 9 | 0.190 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 214 | 0.180 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 72 | 0.180 |
Why?
|
| beta-Lactamases | 2 | 2016 | 33 | 0.170 |
Why?
|
| Escherichia coli | 2 | 2019 | 368 | 0.170 |
Why?
|
| Gram-Negative Bacteria | 2 | 2018 | 55 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2019 | 1553 | 0.160 |
Why?
|
| Staphylococcus aureus | 2 | 2021 | 175 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2020 | 226 | 0.160 |
Why?
|
| beta-Lactam Resistance | 1 | 2018 | 6 | 0.160 |
Why?
|
| Pneumonia, Bacterial | 1 | 2018 | 19 | 0.160 |
Why?
|
| Propensity Score | 1 | 2018 | 117 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2020 | 2358 | 0.150 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 19 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2019 | 163 | 0.150 |
Why?
|
| Pyelonephritis | 1 | 2017 | 17 | 0.150 |
Why?
|
| Levofloxacin | 1 | 2017 | 23 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2021 | 413 | 0.140 |
Why?
|
| Education, Pharmacy | 1 | 2018 | 102 | 0.140 |
Why?
|
| Hospitals | 4 | 2021 | 265 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2279 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2017 | 714 | 0.130 |
Why?
|
| Time Factors | 3 | 2019 | 4655 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2016 | 174 | 0.130 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.130 |
Why?
|
| Biotransformation | 1 | 2015 | 69 | 0.130 |
Why?
|
| Ophthalmoplegia | 1 | 2015 | 20 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 78 | 0.120 |
Why?
|
| Prodrugs | 1 | 2015 | 54 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 124 | 0.120 |
Why?
|
| Optic Nerve | 1 | 2015 | 55 | 0.120 |
Why?
|
| Nervous System | 1 | 2014 | 45 | 0.120 |
Why?
|
| Creatinine | 1 | 2015 | 243 | 0.120 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 245 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2014 | 223 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 365 | 0.110 |
Why?
|
| Length of Stay | 1 | 2016 | 780 | 0.110 |
Why?
|
| Body Weight | 1 | 2015 | 554 | 0.110 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 172 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2015 | 867 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2015 | 706 | 0.100 |
Why?
|
| Prescriptions | 2 | 2020 | 28 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1745 | 0.090 |
Why?
|
| Adolescent | 3 | 2020 | 8912 | 0.090 |
Why?
|
| Kidney | 1 | 2014 | 945 | 0.090 |
Why?
|
| Drug Resistance, Microbial | 2 | 2020 | 70 | 0.080 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 127 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2017 | 7029 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2015 | 3705 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2017 | 216 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 1603 | 0.060 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.060 |
Why?
|
| Logistic Models | 2 | 2016 | 1420 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2800 | 0.050 |
Why?
|
| Enterococcus | 1 | 2022 | 29 | 0.050 |
Why?
|
| Societies | 1 | 2021 | 15 | 0.050 |
Why?
|
| Mentors | 1 | 2021 | 81 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 2007 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 107 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 334 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 22 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 319 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 304 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2021 | 188 | 0.040 |
Why?
|
| Serogroup | 1 | 2019 | 6 | 0.040 |
Why?
|
| Seasons | 1 | 2019 | 129 | 0.040 |
Why?
|
| Preceptorship | 1 | 2018 | 35 | 0.040 |
Why?
|
| Infection Control | 1 | 2019 | 101 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2019 | 206 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 186 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 445 | 0.040 |
Why?
|
| Biological Availability | 1 | 2016 | 79 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2016 | 64 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2016 | 281 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 567 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 2891 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 3187 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 694 | 0.020 |
Why?
|
| United States | 1 | 2022 | 7367 | 0.020 |
Why?
|
| Child | 1 | 2019 | 6405 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2223 | 0.020 |
Why?
|